Journal of Clinical Oncology, Vol 15, 3171-3177, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer

ZU Rahman, DK Frye, AU Buzdar, TL Smith, L Asmar, RE Champlin and GN Hortobagyi
Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA. zrahman@notes.mdacc.tmc.edu

PURPOSE: Most of the data about high-dose chemotherapy (HDCT) for metastatic breast cancer are derived from phase II studies. The interpretation of these data depends on comparisons with data from properly selected historical control patients treated with standard therapy under similar circumstances. We report the long-term results of patients with metastatic breast cancer who were eligible for HDCT but were treated with doxorubicin-containing standard-dose chemotherapy. PATIENTS AND METHODS: Prospectively collected data from 18 successive doxorubicin-containing protocols for the treatment of metastatic breast cancer were evaluated. Using common eligibility criteria for HDCT, we identified patients who would have been candidates for HDCT. We analyzed response rates, progression-free survival (PFS), and overall survival (OS) for all patients, potential HDCT candidates, and noncandidates. RESULTS: A total of 1,581 patients was enrolled onto the 18 studies. Six hundred forty-five were HDCT candidates, and 936 were noncandidates. The complete response rate was 27% for HDCT candidates and 7% for noncandidates; median PFS was 16 and 8 months and median OS was 30 and 17 months, respectively. Survival rates for HDCT candidates and noncandidates, respectively, were 21% and 6% at 5 years and 7% and 2% at 10 years. CONCLUSION: This study suggests that encouraging results of single-arm trials of HDCT could partially be due to selection of patients with better prognoses and further stresses the importance of completing ongoing randomized trials of HDCT to assess the relative efficacy of HDCT in patients with metastatic breast cancer.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Crump, S. Gluck, D. Tu, D. Stewart, M. Levine, P. Kirkbride, J. Dancey, S. O'Reilly, T. Shore, S. Couban, et al. Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16 J. Clin. Oncol., January 1, 2008; 26(1): 37 - 43. [Abstract] [Full Text] [PDF]

				H. C.F. Moore, S. J. Green, J. R. Gralow, S. I. Bearman, D. Lew, W. E. Barlow, C. Hudis, A. C. Wolff, J. N. Ingle, H. K. Chew, et al. Intensive Dose-Dense Compared With High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623 J. Clin. Oncol., May 1, 2007; 25(13): 1677 - 1682. [Abstract] [Full Text] [PDF]

				M. J. Hassett, A. J. O'Malley, J. R. Pakes, J. P. Newhouse, and C. C. Earle Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst, August 16, 2006; 98(16): 1108 - 1117. [Abstract] [Full Text] [PDF]

				M. Mayer Listen to all the voices: an advocate's perspective on early access to investigational therapies Clinical Trials, April 1, 2006; 3(2): 149 - 153. [Abstract] [PDF]

				S. Madersbacher, G. N. Thalmann, J. C. Fritsch, and U. E. Studer Is Eligibility for a Chemotherapy Protocol a Good Prognostic Factor for Invasive Bladder Cancer After Radical Cystectomy? J. Clin. Oncol., October 15, 2004; 22(20): 4103 - 4108. [Abstract] [Full Text] [PDF]

				R. C. F. Leonard, M. Lind, C. Twelves, R. Coleman, S. van Belle, C. Wilson, J. Ledermann, I. Kennedy, P. Barrett-Lee, T. Perren, et al. Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial J Natl Cancer Inst, July 21, 2004; 96(14): 1076 - 1083. [Abstract] [Full Text] [PDF]

				G. N. Hortobagyi What Is the Role of High-Dose Chemotherapy in the Era of Targeted Therapies? J. Clin. Oncol., June 15, 2004; 22(12): 2263 - 2266. [Full Text] [PDF]

				L. E Eberly, J. D Neaton, A. J Thomas, Y. Dai, and Multiple Risk Factor Intervention Trial Research G Multiple-stage screening and mortality in the Multiple Risk Factor Intervention Trial Clinical Trials, April 1, 2004; 1(2): 148 - 161. [Abstract] [PDF]

				S. M. Ali, L. M. Demers, K. Leitzel, H. A. Harvey, D. Clemens, N. Mallinak, L. Engle, V. Chinchilli, L. Costa, C. Brady, et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis Ann. Onc., March 1, 2004; 15(3): 455 - 459. [Abstract] [Full Text] [PDF]

				M. Nottage and L. L. Siu Principles of Clinical Trial Design J. Clin. Oncol., September 15, 2002; 20(90001): 42s - 46. [Full Text] [PDF]

				S. M. Ali, K. Leitzel, V. M. Chinchilli, L. Engle, L. Demers, H. A. Harvey, W. Carney, J. W. Allard, and A. Lipton Relationship of Serum HER-2/neu and Serum CA 15-3 in Patients with Metastatic Breast Cancer Clin. Chem., August 1, 2002; 48(8): 1314 - 1320. [Abstract] [Full Text] [PDF]

				A. Schneeweiss, M. Hensel, P. Sinn, T. Khbeis, R. Haas, G. Bastert, and A. D. Ho Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose Ann. Onc., May 1, 2002; 13(5): 679 - 688. [Abstract] [Full Text] [PDF]

				Y. Nieto, S. Nawaz, R. B. Jones, E. J. Shpall, P. J. Cagnoni, P. A. McSweeney, A. Baron, C. Razook, S. Matthes, and S. I. Bearman Prognostic Model for Relapse After High-Dose Chemotherapy With Autologous Stem-Cell Transplantation for Stage IV Oligometastatic Breast Cancer J. Clin. Oncol., February 1, 2002; 20(3): 707 - 718. [Abstract] [Full Text] [PDF]

				D. A. Berry, G. Broadwater, J. P. Klein, K. Antman, J. Aisner, J. Bitran, M. Costanza, C. O. Freytes, E. Stadtmauer, R. P. Gale, et al. High-Dose Versus Standard Chemotherapy in Metastatic Breast Cancer: Comparison of Cancer and Leukemia Group B Trials With Data From the Autologous Blood and Marrow Transplant Registry J. Clin. Oncol., February 1, 2002; 20(3): 743 - 750. [Abstract] [Full Text] [PDF]

				A. Dispenzieri, M. Q. Lacy, R. A. Kyle, T. M. Therneau, D. R. Larson, S. V. Rajkumar, R. Fonseca, P. R. Greipp, T. E. Witzig, J. A. Lust, et al. Eligibility for Hematopoietic Stem-Cell Transplantation for Primary Systemic Amyloidosis Is a Favorable Prognostic Factor for Survival J. Clin. Oncol., July 15, 2001; 19(14): 3350 - 3356. [Abstract] [Full Text] [PDF]

				R. B. Weiss, G. G. Gill, and C. A. Hudis An On-Site Audit of the South African Trial of High-Dose Chemotherapy for Metastatic Breast Cancer and Associated Publications J. Clin. Oncol., June 1, 2001; 999(1): 1 - 8. [Abstract] [Full Text]

				R. B. Weiss, G. G. Gill, and C. A. Hudis An On-Site Audit of the South African Trial of High-Dose Chemotherapy for Metastatic Breast Cancer and Associated Publications J. Clin. Oncol., June 1, 2001; 19(11): 2771 - 2777. [Abstract] [Full Text] [PDF]

				F. J. Esteva, V. Valero, L. Pusztai, L. Boehnke-Michaud, A. U. Buzdar, and G. N. Hortobagyi Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond Oncologist, April 1, 2001; 6(2): 133 - 146. [Abstract] [Full Text]

				E. A. Stadtmauer, A. O'Neill, L. J. Goldstein, P. A. Crilley, K. F. Mangan, J. N. Ingle, I. Brodsky, S. Martino, H. M. Lazarus, J. K. Erban, et al. Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoietic Stem-Cell Transplantation for Metastatic Breast Cancer N. Engl. J. Med., April 13, 2000; 342(15): 1069 - 1076. [Abstract] [Full Text] [PDF]

				M. E. Lippman High-Dose Chemotherapy plus Autologous Bone Marrow Transplantation for Metastatic Breast Cancer N. Engl. J. Med., April 13, 2000; 342(15): 1119 - 1120. [Full Text]

				G. N. Hortobagyi, A. U. Buzdar, R. L. Theriault, V. Valero, D. Frye, D. J. Booser, F. A. Holmes, S. Giralt, I. Khouri, B. Andersson, et al. Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma J Natl Cancer Inst, February 2, 2000; 92(3): 225 - 233. [Abstract] [Full Text] [PDF]

				W. P. Peters, R. D. Dansey, J. L. Klein, and R. D. Baynes High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation in the Treatment of Breast Cancer Oncologist, February 1, 2000; 5(1): 1 - 13. [Abstract] [Full Text]

				J. O'Shaughnessy High Dose Chemotherapy for Breast Cancer: Taking Stock Oncologist, February 1, 2000; 5(1): 14 - 17. [Full Text]

				P. A. Rowlings, S. F. Williams, K. H. Antman, K. K. Fields, J. W. Fay, E. Reed, C. J. Pelz, J. P. Klein, K. A. Sobocinski, M. J. Kennedy, et al. Factors Correlated With Progression-Free Survival After High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Metastatic Breast Cancer JAMA, October 13, 1999; 282(14): 1335 - 1343. [Abstract] [Full Text] [PDF]

				Y. Nieto, P. J. Cagnoni, E. J. Shpall, S. Matthes, A. Baron, R. B. Jones, and S. I. Bearman Phase II Trial of High-Dose Chemotherapy with Autologous Stem Cell Transplant for Stage IV Breast Cancer with Minimal Metastatic Disease Clin. Cancer Res., July 1, 1999; 5(7): 1731 - 1737. [Abstract] [Full Text] [PDF]

				A. C. Stan, D. L. Radu, S. Casares, C. A. Bona, and T.-D. Brumeanu Antineoplastic Efficacy of Doxorubicin Enzymatically Assembled on Galactose Residues of a Monoclonal Antibody Specific for the Carcinoembryonic Antigen Cancer Res., January 1, 1999; 59(1): 115 - 121. [Abstract] [Full Text] [PDF]

				G. N. Hortobagyi Treatment of Breast Cancer N. Engl. J. Med., October 1, 1998; 339(14): 974 - 984. [Full Text] [PDF]

				S. Subramanyan and M. J. Kennedy Breast Cancer: High-Dose Therapy Oncologist, October 1, 1998; 3(5): 289 - 299. [Abstract] [Full Text]